Non-Group Coverage (Group 1) Coverage for Seniors (Group 66) Palliative Coverage (Group 20514, Please note your client may have Group 1 or Group 66 coverage) Child and Family Services (Group 20403) Alberta Child Health Benefit (Group 20400) Children and Youth Services (Group 19824) Income Support (Group 19823) Alberta Human Services (AISH) (Group 19823) Alberta Adult Health Benefit (AAHB) (Group 23609)
For use within an Alberta Drug Benefit List (ADBL) funded combination therapy regimen for the treatment of chronic hepatitis C according to specific eligibility criteria corresponding to the regimen in which it is being administered. Use of ribavirin outside of an ADBL hepatitis C funded regimen will not be reimbursed.
(Refer to Section 3 of the Alberta Drug Benefit List for specific eligibility criteria corresponding to the regimen in which ribavirin is being administered for the treatment of Chronic Hepatitis C.)
Review Status / Past Decisions
Indication
Reviewing Body
Submission Completion Date
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
CDR Recommendation
Review Status
N/A
Expert Committee
2015/06/02
2015/09/01
Under Review
N/A
Expert Committee
2015/06/02
2015/11/01
Under Review
N/A
Expert Committee
2015/06/02
2015/12/01
Special Authorization
N/A
Expert Committee
2015/06/02
2017/04/01
Special Authorization Criteria Change
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2015/06/02
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2015/09/01
CDR Recommendation
Review Status
Under Review
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2015/06/02
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2015/11/01
CDR Recommendation
Review Status
Under Review
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2015/06/02
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2015/12/01
CDR Recommendation
Review Status
Special Authorization
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2015/06/02
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2017/04/01
CDR Recommendation
Review Status
Special Authorization Criteria Change
PENDOPHARM INC. (PPH)
Telephone:(514) 340-5045
Toll-Free:
To return to the printable Drug Benefit List and related publications,
click here
Last Updated:
NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.
Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.
Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.